Valeant Pharma (VRX) Misses Q2 EPS by 8c, Reaffirms Guidance; Will Divest Ruconest Rights in N.A.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results
August 9, 2016 6:00 AM EDT2016 Full Year Guidance Reconfirmed
LAVAL, Quebec, Aug. 9, 2016 /PRNewswire/ --
Total Revenues of $2.4 billion, a decrease of 11% versus the second quarter of 2015 GAAP EPS Â ($0.88) and Adjusted EPS (non-GAAP) Â $1.40 Cash Flow from Operations of $448 million, an increase of 9% versus the second quarter of 2015Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) ("Valeant" or the "Company") today announced second quarter 2016 financial results.
"We continue to make progress towards stabilizing the... More
